Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

Simon, James A.; Al-Hendy, Ayman; Archer, David F.; Barnhart, Kurt T.; Bradley, Linda D.; Carr, Bruce R.; Dayspring, Thomas; Feinberg, Eve C.; Gillispie, Veronica; Hurtado, Sandra; Kim, Jin Hee; Liu, Ran; Owens, Charlotte D.; Muneyyirci-Delale, Ozgul; Wang, Alice; Watts, Nelson B.; Schlaff, William D.

doi:10.1097/aog.0000000000003869

Cited by 48 publications

(66 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of new therapeutic options, including long-term, well-tolerated medical treatments [71][72][73][74][75], the paradigm will potentially change, and give patients the opportunity to use long-term medical therapies indicated specifically for UF. Assessing and communicating the benefits and risks of all choices for women with UF will remain key to ensuring that our patients receive the best available treatment to meet their individual needs.…”

Section: Considerations For Future Management Of Our Patients With Ufmentioning

confidence: 99%

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication—A Systematic Review

Madueke-Laveaux

Elsharoud

Al-Hendy

2021

JCM

Self Cite

View full text Add to dashboard Cite

Hysterectomy is the most common treatment option in women with uterine fibroids, providing definitive relief from the associated burdensome symptoms. As with all surgical interventions, hysterectomy is associated with risk of complications, short-term morbidities, and mortality, all of which have been described previously. However, information on the potential long-term risks of hysterectomy is only recently becoming available. A systematic literature review was performed to identify studies published between 2005 and December 2020 evaluating the long-term impact of hysterectomy on patient outcomes. A total of 29 relevant studies were identified. A review of the articles showed that hysterectomy may increase the risk of cardiovascular events, certain cancers, the need for further surgery, early ovarian failure and menopause, depression, and other outcomes. It is important to acknowledge that the available studies examine possible associations and hypotheses rather than causality, and there is a need to establish higher quality studies to truly evaluate the long-term consequences of hysterectomy. However, it is of value to consider these findings when discussing the benefits and risks of all treatment options with patients with uterine fibroids to allow for preference-based choices to be made in a shared decision-making process. This is key to ensuring that patients receive the treatment that best meets their individual needs.

show abstract

Section: Considerations For Future Management Of Our Patients With Ufmentioning

confidence: 99%

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication—A Systematic Review

Madueke-Laveaux

Elsharoud

Al-Hendy

2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…GnRH analogs faced the chance of becoming a new trend in this indication, especially after they were introduced into the market in the oral form, for example, elagolix [188] or linzagolix [189]. An increasing number of studies published recently have shown their beneficial influence on UFs and UF-related manifestations [190,191].…”

Section: New Trends and Possible Future Role Of Vitamins In Uterine Fmentioning

confidence: 99%

Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance

Ciebiera

Ali

Zgliczyńska

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Uterine fibroid (UF) is the most common benign tumor pathology of the female reproductive organs. UFs constitute the main reason for a hysterectomy and hospitalization due to gynecological conditions. UFs consist of uterine smooth muscle immersed in a large amount of extracellular matrix (ECM). Genetic studies have demonstrated that UFs are monoclonal tumors originating from the myometrial stem cells that have underwent specific molecular changes to tumor initiating stem cells which proliferate and differentiate later under the influence of steroid hormones. There is growing interest in the role of micronutrients, for example, vitamins, in UFs. This article is a comprehensive review of publications regarding the available data concerning the role of vitamins in the biology and management of UFs. In summary, the results showed that some vitamins are important in the biology and pathophysiology of UFs. For example, vitamins A and D deserve particular attention following studies of their influence on the treatment of UF tumors. Vitamins B3, C, and E have not been as widely studied as the abovementioned vitamins. However, more research could reveal their potential role in UF biology.

show abstract

“…12 The initial trials were extended to 12 months with two groups: elagolix 300 mg twice daily plus low-dose hormone add-back with 1 mg estradiol and 0.5 mg norethindrone acetate once daily (n = 218) or elagolix 300 mg twice daily (elagolix alone) (n = 98). 13 Following 12 months of treatment, heavy menstrual bleeding was controlled in 88% and 89% of women treated with elagolix plus add-back and elagolix alone, respectively. Amenorrhea was reported by 65% of the women in the elagolix plus add-back group.…”

Section: Leuprolide Acetatementioning

confidence: 98%

“…Two women developed liver transaminase levels >3 times the upper limit of normal, resulting in one woman discontinuing treatment. 13 Contraindications to Oriahnn include known allergies to the components of the medication (including the yellow dye tartrazine); high risk of arterial, venous thrombotic or thromboembolic disorders; pregnancy; known osteoporosis; current breast cancer or other hormonally-sensitive malignancies; known liver disease; and concurrent use of organic anion transporting polypeptide 1B1 inhibitors, which includes many HIV antiviral medications. 14 Undiagnosed AUB is a contraindication, and all women prescribed Oriahnn should have endometrial sampling before initiating treatment.…”

Section: Leuprolide Acetatementioning

confidence: 99%

New hormonal medical treatment is an important advance for AUB caused by uterine fibroids

Barbieri¹

2020

OBGM

View full text Add to dashboard Cite

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

Abstract: BR, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol 2020;135. The authors provided this information as a supplement to their article.

Cited by 48 publications

References 24 publications

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication—A Systematic Review

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication—A Systematic Review

Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance

New hormonal medical treatment is an important advance for AUB caused by uterine fibroids

Contact Info

Product

Resources

About